Since stimulation of utrophin expression may be one mechanism by which DMD patients benefit from glucocorticoid treatment, it thus becomes important to define the molecular targets through which these drugs act to increase utrophin expression in muscle cells. This evidence concerns the gene UTRN and Duchenne muscular dystrophy.